Review





Similar Products

total-jnk1/2/3  (ABclonal Biotechnology)
90
ABclonal Biotechnology total-jnk1/2/3
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total Jnk1/2/3, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total-jnk1/2/3/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
total-jnk1/2/3 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
total jnk1 2  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology total jnk1 2
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total Jnk1 2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total jnk1 2/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
total jnk1 2 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
total jnk1/2/3 (1:1000)  (ZenBio)
90
ZenBio total jnk1/2/3 (1:1000)
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total Jnk1/2/3 (1:1000), supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total jnk1/2/3 (1:1000)/product/ZenBio
Average 90 stars, based on 1 article reviews
total jnk1/2/3 (1:1000) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
total jnk1/2/3 antibody  (ZenBio)
90
ZenBio total jnk1/2/3 antibody
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total Jnk1/2/3 Antibody, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total jnk1/2/3 antibody/product/ZenBio
Average 90 stars, based on 1 article reviews
total jnk1/2/3 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
total jnk1 2  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc total jnk1 2
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total Jnk1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total jnk1 2/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
total jnk1 2 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
total c-jun n-terminal kinase 1/2 (jnk1/2  (Millipore)
90
Millipore total c-jun n-terminal kinase 1/2 (jnk1/2
(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated <t>JNK1/2/3</t> and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.
Total C Jun N Terminal Kinase 1/2 (Jnk1/2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/total c-jun n-terminal kinase 1/2 (jnk1/2/product/Millipore
Average 90 stars, based on 1 article reviews
total c-jun n-terminal kinase 1/2 (jnk1/2 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


(A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated JNK1/2/3 and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.

Journal: bioRxiv

Article Title: Glioma-associated fibroblasts promote glioblastoma resistance to temozolomide through CCL2-CCR2 paracrine signaling

doi: 10.1101/2024.03.05.581575

Figure Lengend Snippet: (A) Gene Set Enrichment analysis of differentially expressed genes on the MAPK pathway in glioma cells (U87 and A172) cultured in control medium or GAF conditioned medium. Adjusted p value, the estimated probability that a set with a given Normalized Enrichment Score represents a false positive finding (n = 6 per group). (B) WB analysis of three key molecules, such as phosphorylated ERK1/2(Thr202/Tyr204) and total ERK1/2, phosphorylated p38MAPK and total p38MAPK, and phosphorylated JNK1/2/3 and total JNK1/2/3, of MAPK signaling pathway of U87 cells cultured with Ctr-CM or GAF-CM for 48 hours following TMZ treatment respectively (C) Quantification of protein levels (4 different GAFs were used for this experiment). (D) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for 6 hours, followed by U87 cells or GAFs coculture for 24 hours. (E) Quantification of apoptotic GBM cells (n = 4 per group). (F) Representative flow cytometry plots of apoptotic analyses of U87 cells following TMZ treatment for 48 hours. U87 cells were pretreated with Trametinib (100nmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (G) Quantification of apoptotic GBM cells (n = 4 per group). (H) Representative flow cytometry plots of apoptotic analyses of U87 cells. U87 cells were pretreated with Ravoxertinib (20µmol/L) or DMSO for six hours, then cultured with Ctr-CM or GAF-CM for 48 hours. (I) Quantification of apoptotic GBM cells (n = 4 per group). (J) WB analysis of cleaved-caspase9, cleaved-caspase3, and phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in U87 cells with indicated treatment. (K-M) Quantification of protein levels (4 different GAFs were used for this experiment). (N) WB analysis of cleaved-caspase3 and phosphorylated ERK1/2 (Thr202/Tyr204), and total ERK1/2 in U87 cells with indicated treatment. (O-P) Quantification of protein levels (3 different GAFs were used for this experiment). Data in C, E, G, I, K-M, and N-P were mean±SEM. p values from empirical phenotype-based permutation tests and adjusted using the False Discovery Rate (FDR) procedure (A), two-tailed student-t-test (C, E, G, I, K-M, and N-P). * P < 0.05, ** P < 0.005, *** P < 0.001, **** P < 0.0001, ns = no significant.

Article Snippet: Information of primary antibodies was as follows: Fibronectin (BD Biosciences #610077), α-SMA (Proteintech #55135-1-AP), Cleaved-caspase3 (Cell Signaling Technology #9661), Cleaved-caspase9 (Cell Signaling Technology #9509), Bax (Millipore #ABC11), β-Tublin (Millipore #MAB3408), β-Actin (Cell Signaling Technology #3700), GAPDH (Proteintech #CL594-60004), Phospho-ERK1/2(Thr202/Tyr204) (Cell Signaling Technology #4370S), total-ERK1/2 (Cell Signaling Technology #4696), Phospho-p38 MAPK (T180/Y182) (Abclonal #AP1165), total-p38 MAPK (Abcam #ab308333), Phospho-JNK1-T183/Y185+JNK2-T183/Y185+JNK3-T221/Y223 (Abclonal #AP0276), total-JNK1/2/3 (Abclonal #A4867), CCL2/MCP1 (Abclonal # A23288).

Techniques: Cell Culture, Flow Cytometry, Two Tailed Test